Maxime Dely: How Long Can Europe Rely on U.S. Plasma
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The core issue is clear: American Dependence: How long can Europe rely on U.S. Plasma?
In 2024, nearly 70 % of the world’s plasma used to produce plasma-derived medicinal products came from the United States. A figure that clearly shows how vulnerable Europe remains in a domain essential to patient care.
The U.S. collects around 50 million liters of plasma each year, enabled by a highly industrialized model, a dense network of donation centers, and financial compensation for donors.
By contrast, Europe collects only about 9 million liters, mostly concentrated in Austria, Germany, Hungary, and the Czech Republic. The rest of the continent remains largely dependent on imports.
Since 2023, global demand has been rising quickly (+ 12 to + 14%), driven by increased needs for immunoglobulins. But European collection is growing too slowly to close the gap.
To strengthen supply security, Europe has launched several initiatives:
โช๏ธ EU4Health and resilience programs,
โช๏ธ Investments to modernize collection infrastructures,
โช๏ธ Efforts to increase voluntary non-remunerated donations,
โช๏ธ Expansion of local fractionation capacity.
These initiatives represent real progress, but they come after years of structural dependence. Achieving European plasma sovereignty will require coordinated, long-term, and ambitious action.
The core issue is clear: ensuring continuous and secure access to plasma-derived medicines for all European patients.
In your review, what should be the top priority to rebalance this dependency?
Boosting collection? Rethinking the model? Investing in local production?”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Mรผller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session